Project Grant R01CA293936
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$619K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is focused on developing a novel immunochemotherapy approach for treating metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award (1/9/2025 - 12/31/2029) include: Developing and characterizing a nanocarrier platform (PCL-CP) capable of co-delivering siRNA targeting the IRHOM1 gene and a prodrug conjugate of camptothecin...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $628,499 to the University of California, Los Angeles to develop innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma. The research framework includes mechanistic studies to optimize mRNA-encoded antigen and adjuvant properties, evaluate the new vaccines in humanized immune system mouse models,...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
The National Cancer Institute (NCI) awarded Case Western Reserve University (CWRU) a 5-year, $654,681 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative anticancer nanovaccines for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this grant include: Designing and developing multifunctional ionizable lipid nanoparticle (ELNP) based peptide vaccines for effective PDAC...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
The National Cancer Institute awarded a $408,829 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to develop positive allosteric modulators (PAMs) targeting the chemokine receptor XCR1. The goal is to enhance XCR1 signaling in the tumor microenvironment to improve the function of cross-presenting dendritic cells and stimulate anti-tumor cytotoxic T cell responses. The project will utilize DNA-encoded library technology to screen for XCR1 PAMs and obtain...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $592,500.00 to the University of California, San Diego to develop a "MUTANT DNA-ACTIVATED KILLING SYSTEM FOR PRECISION BREAST CANCER THERAPY." The award has a performance period from February 1, 2025 to January 31, 2028. The project aims to advance innovative biomedical research and transformative healthcare solutions for military service members...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $2,186,372 to the University of California, Irvine to support a new program project on "Tipping Points in Cancer". The 5-year project, starting April 1, 2025, will investigate fundamental biological processes underlying cancer initiation and progression, using advanced mouse models of chronic myeloid leukemia, melanoma, and triple-negative breast cancer. The project will...